Synexus has announced plans to open three new research centers in Bulgaria, Poland and Romania.
Synexus has announced plans to open three new research centers in Bulgaria, Poland and Romania, bringing the company’s total to nine centers in Central & Eastern Europe and a total network of 25 across Europe and Africa.
The population of Central and Eastern Europe exceeds that of either the US or the five largest Western European markets combined, and it also has excellent healthcare professionals, according to the U.K.-headquartered recruitment specialist.
“This will help us to provide much greater support to the global pharmaceutical industry,” noted CEO Christophe Berthoux. “Since we opened our first centre in Poland in 2006 we have had an ongoing programme of investment in the region.”
The new Polish facility is the company’s largest research center in the world. It occupies 1000 m2 at Beniowskiego Street in Gdansk. Magdalena Przekwas-Jaruchowska, M.D., the facility’s director, oversaw the opening ceremony, which included representatives from the local authority, the British Embassy, the medical university and patients’ associations.
Romania’s new 820 m2 center is based in Bucharest, which has a population of two million. The country has been part of Synexus’ development plans since early 2000, as the total population is over 20 million and the number of new clinical trials granted approval during the last five years is at least 200, according to the company.
In Sofia, Bulgaria, the total area of the new center is 650 m2, and it has eight medical rooms, two administration rooms, monitoring and meeting rooms and other areas. This facility aims to offer its patients access to new drugs in the fields of pulmonology, rheumatology, neurology, endocrinology, cardiology, gastroenterology and dermatology.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.